A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT03496207
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 106 participants
- Registry
-
NCT03496207 -
2017-004738-27
-
- Other papers using this trial's data
- Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)
- Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, France, Germany, Israel, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03496207. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-13 (actual); primary completion 2022-03-09 (actual). Results posted on 2023-04-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Acronym
- PULSAR
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sotatercept
- Intervention (Other)
- SOC
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Record details
- Record id
cardio:ct-nct03496207- Content hash
ac34c0b5f4c1a0ab79732dcc5300c17d28a87a06eb2932464160645b6c3391ec